08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
Who's the "swing vote," the "parade of horribles," and more. I'm sorry that I haven't blogged latel...
Read More >
GDPR requires businesses to be transparent, fair, and proportionate in how they collect process and ...
Read More >
"Stock Purchase” • Pre-closing tax basis in assets is carried over; no step-up in tax basis. Reve...
Read More >
Last week, the National Labor Relations Board (“Board”) held that employer policies that prohibit ...
Read More >
As the COVID-19 pandemic continues, owners and developers find themselves facing the prospect of con...
Read More >
We know August was exhausting for employers – New York, New Jersey, Maine, Colorado, and yes, even ...
Read More >